Evidence map›Paper›PMID 39281669›Full record

ArticleFrontiers in immunology2024

Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters.

Peter Zhou, Jacqueline Watt, Juntao Mai, Huibi Cao, Zhijie Li, Ziyan Chen, Rongqi Duan, Ying Quan, Anne-Claude Gingras, James M Rini and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. IgA binding characteristics of golden hamster and ferret Fcα receptors.Journal of immunology (Baltimore, Md. : 1950) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peter Zhou *Department of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Jacqueline Watt *Department of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Juntao MaiDepartment of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Huibi CaoTranslational Medicine Program, Hospital for Sick Children Research Institute, Toronto, ON, Canada.
Zhijie LiDepartment of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Ziyan ChenTranslational Medicine Program, Hospital for Sick Children Research Institute, Toronto, ON, Canada.
Rongqi DuanTranslational Medicine Program, Hospital for Sick Children Research Institute, Toronto, ON, Canada.
Ying QuanDepartment of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Anne-Claude GingrasDepartment of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
James M RiniDepartment of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Jim HuTranslational Medicine Program, Hospital for Sick Children Research Institute, Toronto, ON, Canada.
Jun LiuDepartment of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outbreak of coronavirus disease 19 (COVID-19) has highlighted the demand for vaccines that are safe and effective in inducing systemic and airway mucosal immunity against the aerosol transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this study, we developed a novel helper-dependent adenoviral vector-based COVID-19 mucosal vaccine encoding a full-length SARS-CoV-2 spike protein (HD-Ad-FS). Through intranasal immunization (single-dose and prime-boost regimens), we demonstrated that the HD-Ad-FS was immunogenic and elicited potent systemic and airway mucosal protection in BALB/c mice, transgenic ACE2 (hACE2) mice, and hamsters. We detected high titers of neutralizing antibodies (NAbs) in sera and bronchoalveolar lavages (BALs) in the vaccinated animals. High levels of spike-specific secretory IgA (sIgA) and IgG were induced in the airway of the vaccinated animals. The single-dose HD-Ad-FS elicited a strong immune response and protected animals from SARS-CoV-2 infection. In addition, the prime-boost vaccination induced cross-reactive serum NAbs against variants of concern (VOCs; Beta, Delta, and Omicron). After challenge, VOC infectious viral particles were at undetectable or minimal levels in the lower airway. Our findings highlight the potential of airway delivery of HD-Ad-FS as a safe and effective vaccine platform for generating mucosal protection against SARS-CoV-2 and its VOCs.

Indexed as

Administration, IntranasalAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesImmunity, MucosalMice, Inbred BALB CSARS-CoV-2Spike Glycoprotein, CoronavirusAdenoviridaeAngiotensin-Converting Enzyme 2AnimalsCricetinaeFemaleHumansMesocricetusAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2adenoviral vectorCOVID-19HD-Adintranasal deliverySARS-CoV-2vaccine

Identifiers

PMID39281669
PMCPMC11392758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.